News & Updates
Filter by Specialty:
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
In patients with clear cell renal cell carcinoma (RCC), adjuvant pembrolizumab continues to improve disease-free survival (DFS) over placebo, according to extended follow-up of the phase III KEYNOTE-564 trial.
Adjuvant pembrolizumab continues to improve DFS in clear cell RCC
28 Sep 2022
Vision impairment tied to depression, anxiety in children
Children with vision impairment are at higher risk of developing symptoms of depression and anxiety, according to a study, noting that surgical treatment of strabismus may improve these symptoms.
Vision impairment tied to depression, anxiety in children
28 Sep 2022
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
A single dose of FINLAY-FR-1A, a recombinant d-RBD*-based COVID-19 vaccine, strengthens pre-existing natural immunity in patients who have recovered from asymptomatic, mild or moderate COVID-19, and has an excellent safety profile, a phase IIa/b study has shown.
FINLAY-FR-1A vaccine boosts natural immunity in COVID-19 convalescents
28 Sep 2022
First-line, reduced-dose eribulin mesylate disappoints in older adults with metastatic breast cancer
Among older patients with metastatic breast cancer, first-line treatment with reduced-dose eribulin mesylate is reasonably safe but yields a low disease control rate, reports a recent phase II trial.
